XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUE Disaggregated Revenue Table (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Disaggregation of Revenue [Line Items]          
Accounts Receivable, Allowance for Credit Loss $ 32.8   $ 32.8   $ 30.7
Unbilled Services, Allowance for Credit Loss 8.9   8.9   10.5
Note Receivable, Allowance for Credit Loss 0.7   0.7   0.7
Allowance for Credit Loss 42.4   42.4   41.9
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     6.2    
Allowance for Credit Loss, Write Off     (5.7)    
Deferred Revenue, Revenue Recognized 6.3 $ 9.3 79.1 $ 65.9  
Contract with Customer, Asset, before Allowance for Credit Loss 116.9   116.9   222.3
Contract with Customer, Liability 360.8   360.8   310.6
Unbilled Contracts Receivable $ 108.0   $ 108.0   211.8
Percent of Revenue Contributed 100.00% 100.00% 100.00% 100.00%  
Revenues $ 3,056.8 $ 2,866.8 $ 9,128.3 $ 8,934.2  
Accounts Receivable, after Allowance for Credit Loss, Current 1,957.0   1,957.0   1,785.5
Allowance for Credit Loss, Receivable, Other, Current (8.9)   (8.9)   (10.5)
Contract with Customer, Asset, after Allowance for Credit Loss, Current $ 108.0   $ 108.0   211.8
Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 9.00% 9.00% 9.00% 9.00%  
North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 87.00% 87.00% 87.00% 87.00%  
Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 4.00% 4.00% 4.00% 4.00%  
UNITED STATES          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 83.40% 83.50% 83.80% 83.40%  
Revenues $ 2,550.6 $ 2,392.4 $ 7,645.0 $ 7,454.0  
Medicare and Medicaid [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 8.00% 8.00% 8.00% 8.00%  
LabCorp Diagnostics [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 77.00% 77.00% 77.00% 77.00%  
LabCorp Diagnostics [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 77.00% 77.00% 77.00% 77.00%  
LabCorp Diagnostics [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 24.00% 23.00% 24.00% 22.00%  
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 24.00% 23.00% 24.00% 22.00%  
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 9.00% 8.00% 9.00% 8.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 9.00% 8.00% 9.00% 8.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 8.00% 8.00% 8.00% 8.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 36.00% 38.00% 36.00% 39.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 36.00% 38.00% 36.00% 39.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   23.00%   23.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   9.00%   9.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   10.00%   10.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed   4.00%   4.00%  
Diagnostics          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 77.00%        
Accounts Receivable, before Allowance for Credit Loss $ 1,160.0   $ 1,160.0   1,046.9
Drug Development          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 23.00%        
Accounts Receivable, before Allowance for Credit Loss $ 829.8   $ 829.8   $ 769.3
Drug Development | Biopharmaceutical and medical device companies [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 23.00%   23.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 9.00%   9.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 10.00%   10.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 4.00%   4.00%    
Notes Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     $ 0.0    
Allowance for Credit Loss, Write Off     0.0    
Unbilled Contracts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     0.0    
Allowance for Credit Loss, Write Off     (1.6)    
Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     6.2    
Allowance for Credit Loss, Write Off     $ (4.1)